Michelle Berg rejoined Aldevron in May 2019, serving in the newly formed role of president of the GMP nucleic acids business unit where she oversees company strategy to provide GMP plasmids and mRNA for gene editing, gene therapy, and cell therapy applications. Previous tenure with Aldevron began as the company’s first hire in 1998, helping to develop the services and client-focused approach the company is known for through numerous roles with increasing reach and responsibility. From June 2015 to early May 2019, Michelle served as vice president of patient affairs and community engagement for Abeona Therapeutics, a now clinical-stage gene and cell therapy company focused on patients with rare diseases, where she was a driving member of the company’s growth and translation into the clinic. She is a contributing author and speaker on patient-focused programming, rare disease advocacy, and accessible education on genetic medicines. In addition to her roles with Abeona and Aldevron, she has performed research on behalf of the Department of Plant Sciences at North Dakota State University where she also received her B.S. in biotechnology in 1997.